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Abstract 
The occurrence of acute ischemic colitis may be associated with the intake of various 
drugs. However, colitis during antineoplastic chemotherapy usually is due to toxic effects 
or neutropenia and not caused by ischemia. We describe a 51-year-old man with jejunal 
B-cell lymphoma who developed recurrent episodes of ischemic colitis following 
chemotherapy with cyclophosphamide, vincristine, doxorubicine and prednisolone plus 
rituximab (R-CHOP). After switching chemotherapy to bendamustin plus rituximab no 
further episodes of colonic ischemia occurred during the following cycles of 
chemotherapy. In conclusion, chemotherapy of lymphoma using a standard protocol 
with CHOP and rituximab may cause ischemic colitis. 
Introduction 
Ischemic colitis is the most common form of intestinal ischemia [1]. The disease often 
occurs spontaneously, especially in the elder population with underlying atherosclerosis, 
and is caused by embolic or thrombotic occlusion of colonic vessels or by conditions 
leading to hypoperfusion of the colonic wall (nonocclusive form). The typical clinical 
presentation is sudden onset of left-sided lower abdominal pain often followed by 
hematochezia within 24 h. In most patients the disease is self-limiting, but the severe form 
of ischemic colitis, colonic gangrene, is a life-threatening disease usually requiring urgent 
surgery.  
Multiple predisposing factors for the development of ischemic colitis have been 
identified. These factors include decreased cardiac output caused by shock, arrhythmias, 
congestive heart failure, ongoing cardiac bypass operation or aortic repair. Other reasons 
for colonic ischemia are coagulation disorders such as deficiency of protein C, protein S 
or antithrombin III, sickle cell disease, and vasculitis disorders such as systemic lupus 
erythematosus, polyarteritis nodosa or thromboangiitis obliterans [2].  
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Various drugs including digitalis, vasoconstrictors, antihypertensive drugs, 
psychotropic agents, nonsteroidal anti-inflammatory drugs, and antidiarrheal agents have 
been identified as precipitating factors for colonic ischemia. Antineoplastic drugs such as 
bevacizumab in combination with irinotecan and 5-fluorouracil [3] or docetaxel in 
combination with vinorelbin [4] may cause ischemic colitis. However, therapy for 
non Hodgkin’s lymphoma with cyclophosphamide, vincristine, doxorubicine, 
prednisolone and rituximab (R-CHOP) has not been described as a precipitating factor 
for ischemic colitis. Colitis occurring during antineoplastic chemotherapy is most 
frequently due to direct toxic effects or severe neutropenia. Both toxic effects on the 
colonic mucosa and neutropenic enterocolitis should be differentiated from ischemic 
colitis [5]. 
Here we report the association of recurrent episodes of colonic ischemia in relation to 
standard antineoplastic chemotherapy for B-cell lymphomas. 
Case Report 
A 51-year-old man was referred with recurrent cramping periumbilical pain. Computed 
tomography showed marked jejunal thickening as well as multiple abdominal and thoracic lymphomas. 
Histology taken 200 cm from incisors by double balloon enteroscopy established the diagnosis of jejunal 
B-cell lymphoma. Complete colonoscopy showed no abnormalities. Systemic antineoplastic therapy 
containing the monoclonal antibody rituximab 375 mg/m
2 (day 0), combined with cyclophosphamide 
750 mg/m
2, vincristine 2 mg, doxorubicine 50 mg/m
2 (each given at day 1) and prednisolone 100 mg 
on days 1–5 (R-CHOP) was initiated. Mesna and ondansetron were given for prophylaxis of 
cyclophosphamide-induced cystitis and emesis, respectively.  
Two days after the initiation of chemotherapy the patient was admitted to the emergency 
department because of sudden onset of left-sided lower abdominal pain followed by hematochezia. 
Computed tomography of the abdomen revealed, besides the small bowel lymphoma with lymph node 
involvement, thickening of the descending and sigmoid colon. Laboratory tests including stool analysis 
for enteritis pathogens were unremarkable except for an elevation of C-reactive protein to 23.5 mg/l. 
Colonoscopy showed inflammation with semicircular longitudinal swelling and petechial bleeding in 
the descending and sigmoid colon (fig. 1). Histology from the descending colon showed complete 
necrosis of the superficial epithelium and infiltration of the submucosal layer by polymorphonuclear 
neutrophilic leucocytes consistent with ischemic colitis. The patient had an unremarkable course and 
was discharged 5 days later. The second course of chemotherapy containing CHOP plus rituximab was 
well tolerated, but 4 days after the third course of chemotherapy, the patient presented again with 
sudden onset of diffuse abdominal pain. A new episode of colonic ischemia was diagnosed by a CT 
scan of the abdomen, which showed nearly complete regression of the lymphoma, but also marked 
thickening of the entire colon wall. Laboratory tests again showed no neutropenia, but a rise of 
C-reactive protein to 69.7 mg/l. The second episode of ischemic colitis was also managed conservatively. 
Discussion 
In the present case, differential diagnosis was difficult because the patient initially 
presented with abdominal pain due to jejunal lymphoma. The first episode of colonic 
ischemia was thought to occur spontaneously in a heavy smoker, but the occurrence of 
two clinically typical episodes of ischemic colitis after chemotherapy argues for the 
association of reduced blood supply of the colon following the application of 
chemotherapy. Various drugs have been described as possible triggers for the 
nonocclusive form of ischemic colitis [2]. However, the patient did not take drugs having 
a known association with ischemic colitis. Colitis associated with antineoplastic  
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chemotherapy is usually associated with severe neutropenia 7–10 days after completion 
of the course or with a direct toxic effect [5]. In contrast, colon ischemia seems rare 
during antineoplastic therapy. Some chemotherapeutic drugs such as bevacizumab in 
combination with irinotecan and 5-fluorouracil or docetaxel in combination with 
vinorelbin may cause colon ischemia [3, 4], but chemotherapy according to the R-CHOP 
protocol, which is a standard regime for treatment of non Hodgkin’s lymphoma [6], has 
not been associated with the development of ischemic colitis. 
After switching chemotherapy to bendamustine combined with prednisolone and 
rituximab, no episodes of colon ischemia occurred during the following three cycles. We 
therefore favour cyclophosphamide, doxorubicine or vincristine or the combination, 
respectively, as the cause for the two episodes of colonic ischemia. As illustrated in this 
case, clinicians should be aware of possible ischemic colitis in patients with abdominal 
pain during chemotherapy with the CHOP regime. 
 
 
 
 
 
 
Fig. 1. Colonoscopic view into the descending colon showing mucosal edema, friability and petechial 
hemorrhage. 
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